John Dean

Dr. John Dean

University of Aberdeen, UK
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
SMS J Moore
S J Moore
PTP Turnpenny
P Turnpenny
AQA Quinn
A Quinn
SGS Glover
S Glover
DLD J Lloyd
D J Lloyd
JDJohn Dean
John Dean
BACKGROUND Anticonvulsants taken in pregnancy are associated with an increased risk of malformations and developmental delay in the children. To evaluate the pattern of abnormalities associated with prenatal anticonvulsant exposure further, we undertook a clinical study of 57 children with fetal anticonvulsant syndromes. METHODS Fifty two children were ascertained through the Fetal Anticonvulsant Syndrome Association and five were referred to the Aberdeen Medical Genetics Service. Pregnancy and medical history were obtained through a standardised questionnaire and interview and the children were examined. RESULTS Thirty four (60%) were exposed in utero to valproate alone, four (7%) to carbamazepine alone, four (7%) to phenytoin alone, and 15 (26%) to more than one anticonvulsant. Forty six (81%) reported behavioural problems, 22 (39%) with hyperactivity or poor concentration of whom four (7%) had a diagnosis of attention deficit and hyperactivity disorder. Thirty four (60%) reported two or more autistic features, of whom four had a diagnosis of autism and two of Asperger's syndrome. Forty four (77%) had learning difficulties, 46 (81%) had speech delay, 34 (60%) had gross motor delay, and 24 (42%) had fine motor delay. Nineteen (33%) had glue ear and 40 (70%) had joint laxity involving all sizes of joints. Of 46 who had formal ophthalmic evaluation, 16 (34%) had myopia. CONCLUSIONS Speech delay, joint laxity, glue ear, and myopia are common in the fetal anticonvulsant syndromes and autistic features and hyperactivity form part of the behavioural phenotype.

1 October 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GRGillian Rice
Gillian Rice
TPTeresa Patrick
Teresa Patrick
RPRekha Parmar
Rekha Parmar
CTClaire F. Taylor
Claire F. Taylor
AAAlec Aeby
Alec Aeby
YCYanick J. Crow
Yanick J. Crow

1 April 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
GRGillian Rice
Gillian Rice
WNWilliam Newman
William Newman
JDJohn Dean
John Dean
TPTeresa Patrick
Teresa Patrick
RPRekha Parmar
Rekha Parmar
YCYanick J. Crow
Yanick J. Crow

20 June 2007 in Brain
Verified
Journal Article
Open access
PDF file
RORikke Katrine Jentoft Olsen
Rikke Katrine Jentoft Olsen
SOSimon E. Olpin
Simon E. Olpin
BABrage Storstein Andresen
Brage Storstein Andresen
ZMZofia H. Miedzybrodzka
Zofia H. Miedzybrodzka
MPMorteza Pourfarzam
Morteza Pourfarzam
AMAndrew A. M. Morris
Andrew A. M. Morris
Multiple acyl-CoA dehydrogenation deficiency (MADD) is a disorder of fatty acid, amino acid and choline metabolism that can result from defects in two flavoproteins, electron transfer flavoprotein (ETF) or ETF: ubiquinone oxidoreductase (ETF:QO). Some patients respond to pharmacological doses of riboflavin. It is unknown whether these patients have defects in the flavoproteins themselves or defects in the formation of the cofactor, FAD, from riboflavin. We report 15 patients from 11 pedigrees. All the index cases presented with encephalopathy or muscle weakness or a combination of these symptoms; several had previously suffered cyclical vomiting. Urine organic acid and plasma acyl-carnitine profiles indicated MADD. Clinical and biochemical parameters were either totally or partly corrected after riboflavin treatment. All patients had mutations in the gene for ETF:QO. In one patient, we show that the ETF:QO mutations are associated with a riboflavin-sensitive impairment of ETF:QO activity. This patient also had partial deficiencies of flavin-dependent acyl-CoA dehydrogenases and respiratory chain complexes, most of which were restored to control levels after riboflavin treatment. Low activities of mitochondrial flavoproteins or respiratory chain complexes have been reported previously in two of our patients with ETF:QO mutations. We postulate that riboflavin-responsive MADD may result from defects of ETF:QO combined with general mitochondrial dysfunction. This is the largest collection of riboflavin-responsive MADD patients ever reported, and the first demonstration of the molecular genetic basis for the disorder.

27 February 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LBLouise S Bicknell
Louise S Bicknell
EBErnie M H F Bongers
Ernie M H F Bongers
ALAndrea Leitch
Andrea Leitch
SBStephen Brown
Stephen Brown
JSJeroen Schoots
Jeroen Schoots
AJAndrew P Jackson
Andrew P Jackson
Andrew Jackson, Ernie Bongers and colleagues report the identification of mutations in five genes in individuals with Meier-Gorlin syndrome. The five genes, ORC1, ORC4, ORC6, CDT1 and CDC6, all encode components of the pre-replication complex. Meier-Gorlin syndrome (ear, patella and short-stature syndrome) is an autosomal recessive primordial dwarfism syndrome characterized by absent or hypoplastic patellae and markedly small ears1,2,3. Both pre- and post-natal growth are impaired in this disorder, and although microcephaly is often evident, intellect is usually normal in this syndrome. We report here that individuals with this disorder show marked locus heterogeneity, and we identify mutations in five separate genes: ORC1, ORC4, ORC6, CDT1 and CDC6. All of these genes encode components of the pre-replication complex, implicating defects in replication licensing as the cause of a genetic syndrome with distinct developmental abnormalities.

6 January 2005 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SMSusan J. Moore
Susan J. Moore
JGJane S. Green
Jane S. Green
YFYanli Fan
Yanli Fan
ABAshvinder K. Bhogal
Ashvinder K. Bhogal
EDElizabeth Dicks
Elizabeth Dicks
PPPatrick S. Parfrey
Patrick S. Parfrey